Literature DB >> 9630364

Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.

K Blease1, A Burke-Gaffney, P G Hellewell.   

Abstract

1. Expression of cell adhesion molecules (CAM) on the lung microvascular endothelium is believed to play a key role in the recruitment of leukocytes in pulmonary inflammation. Moreover, regulation of CAM expression may be an important mechanism through which this inflammation may be controlled. Experimental evidence has suggested that combined phosphodiesterase (PDE) 3 and 4 inhibitors increase cyclic AMP levels within cells greater than inhibition of either isoenzyme alone. In the present study we assessed the effect of combinations of rolipram (PDE4 inhibitor), ORG 9935 (PDE3 inhibitor) and salbutamol (beta-agonist) on CAM expression and neutrophil or eosinophil adhesion to human lung microvascular endothelial cells (HLMVEC). 2. Tumour necrosis factor-alpha (TNF-alpha)-induced intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and E-selectin expression were measured on HLMVEC monolayers at 6 h by a specific ELISA technique in the presence of different combinations of medium, rolipram, ORG 9935 and salbutamol. 3. Rolipram in combination with salbutamol, but neither agent alone, inhibited TNF-alpha-induced E-selectin expression, whilst ICAM-1 and VCAM-1 expression were not affected. ORG 9935 had no significant effect on CAM expression alone. However, in combination with rolipram a syngergistic inhibition of VCAM-1 and E-selectin, but not ICAM-1, expression was observed. No further inhibition was seen in the additional presence of salbutamol. 4. Neutrophil adhesion to TNF-alpha-stimulated (6 h) HLMVEC was mainly E-selectin dependent in this model, as ENA2 an anti-E-selectin monoclonal antibody (mAb) abrogated neutrophil adhesion. Eosinophil adhesion was E-selectin-, ICAM-1- and VCAM-1-dependent, as assessed by the inhibitory activity of ENA2 and the ability of a mAb to the ICAM-1 ligand, CD18, and a mAb to the VCAM-1 ligand, VLA4, to attenuate adhesion. 5. Rolipram in the presence of salbutamol or ORG 9935 significantly inhibited neutrophil adherence to TNF-alpha-stimulated HLMVEC. Eosinophil adherence to monolayers was inhibited only when HLMVEC were activated in the presence of rolipram and ORG 9935. 6. Collectively, the findings presented in this manuscript suggest that inhibition of PDE4 with appropriate activation of adenylate cyclase is sufficient to inhibit induction of E-selectin expression on HLMVEC to a level that has functional consequences for neutrophil adhesion. In contrast, combined inhibition of PDE3 and 4 isoenzymes is necessary to inhibit VCAM-1 and to have inhibitory effects on eosinophil adhesion to activated HLMVEC. Upregulation of ICAM-1 expression on HLMVEC does not appear to be modulated by PDE3 and 4 inhibition. These data may have implications for the use of selective PDE4 inhibitors in lung inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630364      PMCID: PMC1565378          DOI: 10.1038/sj.bjp.0701833

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells.

Authors:  William A Sands; Hayley D Woolson; Gillian R Milne; Claire Rutherford; Timothy M Palmer
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

Review 4.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.

Authors:  James F Meschia; Thomas G Brott; Robert D Brown; Richard Crook; Bradford B Worrall; Brett Kissela; W Mark Brown; Stephen S Rich; L Douglas Case; E Whitney Evans; Stephen Hague; Andrew Singleton; John Hardy
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

6.  Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

Authors:  A Alvarez; L Piqueras; M A Blazquez; M J Sanz
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

7.  Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.

Authors:  P M Silva; A C Alves; M F Serra; A L Pires; J P Silva; E O Barreto; R S Cordeiro; P J Jose; M M Teixeira; V Lagente; M A Martins
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

8.  Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Authors:  Naga Srinivas Tripuraneni; Mohammed Afzal Azam
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

Authors:  M-J Sanz; J Cortijo; M A Taha; M Cerdá-Nicolás; E Schatton; B Burgbacher; J Klar; H Tenor; C Schudt; A C Issekutz; A Hatzelmann; E J Morcillo
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.